Application of a Translational Research Platform to Unveil Efficacy Signals and Mechanisms of Resistance of FGFR Inhibitors in Multiple FGFR-Altered Solid Tumors.

doi:10.1158/1078-0432.CCR-26-0300

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Application of a Translational Research Platform to Unveil Efficacy Signals and Mechanisms of Resistance of FGFR Inhibitors in Multiple FGFR-Altered Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2026

Hierro Cinta, Sánchez-Guixé Mònica, Tarcic Gabi, Schwartz Sarit, Hembrough Todd, Moss Tyler, Shaw Kenna R, Meric-Bernstam Funda, Saura Cristina, Oliveira Mafalda, Dienstmann Rodrigo, Jiménez Jose, Nuciforo Paolo, Vivancos Ana, Garralda Elena, Tabernero Josep, Serra Violeta, Rodon Jordi

Abstract excerpt

PURPOSE: The predictive value of fibroblast growth factor receptor (FGFR) amplifications (amp) and the role of FGFR mutations (mut) beyond known activating variants remain unclear. We aimed to establish a translational research platform to characterize FGFR alterations (alt) and explore their potential as predictive biomarkers for FGFR-targeted agents. EXPERIMENTAL DESIGN: This ambispective study included a...

Read the complete abstract on PubMed

Topics

Humans
Drug Resistance, Neoplasm
Animals
Translational Research, Biomedical

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Neoplasms

Receptors, Fibroblast Growth Factor

Protein Kinase Inhibitors

Mice

Xenograft Model Antitumor Assays

Mutation

Biomarkers, Tumor

Proteomics

Gene Amplification

Female

Signal Transduction

Retrospective Studies

Source

Open in PubMed

Identifiers

PMID: 42440358
DOI: 10.1158/1078-0432.CCR-26-0300

Genes

FGFR1
FGFR3
FGFR2
PTEN

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Application of a Translational Research Platform to Unveil Efficacy Signals and Mechanisms of Resistance of FGFR Inhibitors in Multiple FGFR-Altered Solid Tumors.PMID 42440358Read ↗

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.Semantic proximity Read ↗

Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterationsSemantic proximity Read ↗

FGFR a promising druggable target in cancer: Molecular biology and new drugs.Semantic proximity Read ↗

FGFR rearrangements: oncogenic drivers and therapeutic targets.Semantic proximity Read ↗

Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment.Semantic proximity Read ↗

Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.Semantic proximity Read ↗

Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort.Semantic proximity Read ↗

Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy.Semantic proximity Read ↗

A place for precision medicine in bladder cancer: targeting the FGFRs.Semantic proximity Read ↗

Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor–related Apoptosis-inducing Ligand in FGFR3-mutated TumorsSemantic proximity Read ↗

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.Semantic proximity Read ↗

Future applications of FGF/FGFR inhibitors in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.